Reduces blood pressure. Sold as Cleviprex. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Clevidipine (sold as Cleviprex), first approved Aug 1, 2008, with 0 new uses approved and 0 published complete response letters.
| Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort StudyPost-stroke Pneumonia · First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | — | Not yet recruiting | Dec 4, 2025 |
| Clevidipine for the Antihypertensive Treatment of Acute Intracerebral HemorrhageIntracerebral Hemorrhage, Stroke · Zeenat Qureshi Stroke Institute | — | Recruiting | May 7, 2024 |
| Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General AnesthesiaHypertension · University of California, San Diego | Phase 4 | Not yet recruiting | Oct 3, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
